Overview

Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The overall goal of the proposed study is to determine the effectiveness of hydroxyurea therapy for secondary stroke prevention and prevention of other neurological events in children with SCA with an acute overt stroke.

Phase:

Phase 3

Details

Lead Sponsor:

Vanderbilt University
Vanderbilt University Medical Center

Collaborators:

Aminu Kano Teaching Hospital
Murtala Muhammed Specialist Hospital

Treatments:

Hydroxyurea